Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Cofetuzumab Pelidotin in PTK7-Expressing Recurrent NSCLC
jRCT2080225309Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, single-arm trial of cofetuzumab pelidotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc. Primary endpoints: Efficacy outcomes (unspecified primary endpoint) and Safety and tolerability. Started Aug 2020; status: recruiting.
02
Drugs
cofetuzumab pelidotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225309.